2220 GMT - Ord Minnett is confident about its buy call on Regis Healthcare ahead of key reforms to accommodation funding on Nov. 1. It expects these reforms to be a material driver of Regis's medium-term earnings. Central to this is room pricing, known to investors as RAD, says analyst Tom Godfrey. "We note that the company's latest advertised prices have increased 19% since December," to now stand at A$638,000, says Ord Minnett. This is well ahead of its estimates. Ord Minnett says this can raise Regis's RAD funding to A$2.2 billion, from A$1.7 billion. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 15, 2025 18:20 ET (22:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。